Study Stopped
Recruitment was dependent on finding participants that had to receive an initial COVID-19 vaccination and we were unable to find new participants anymore.
Plant Stanol Esters and COVID-19 Vaccination Response
The Effect of Plant Stanol Ester Consumption on the Vaccination Response to a COVID-19 Vaccine
1 other identifier
interventional
48
1 country
1
Brief Summary
Plant stanols are known to lower low-density lipoprotein cholesterol (LDL-C). However, studies have suggested that these compounds also beneficially influence the immune system, e.g. increasing vaccine-specific antibody titers. BMI has previously been negatively associated to vaccination responses. If plant stanols indeed have beneficial effect on the immune system, people with overweight or obesity might benefit from consuming plant stanols prior to receiving the COVID-19 vaccination. The primary objective of this study is to demonstrate clinical benefits of consumption of plant stanols (delivered via products enriched with plant stanol esters) on the vaccination response to a COVID-19 vaccine in overweight or obese patients. The main study endpoint is vaccination response to a COVID-19 vaccine. Secondary endpoints include amongst others hematological, inflammatory and immunological parameters (e.g. hs-CRP, leukocyte differential count) and metabolic markers (e.g. blood lipid profiles, plasma glucose, serum insulin, HOMA-IR).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2021
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 13, 2021
CompletedFirst Posted
Study publicly available on registry
April 14, 2021
CompletedStudy Start
First participant enrolled
April 22, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 11, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 11, 2022
CompletedMarch 2, 2022
February 1, 2022
9 months
April 13, 2021
February 11, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Vaccine specific antibody titers
The response to the COVID-19 vaccine will be measured by quantifying specific antibody titers (vaccine specific IgG and IgM). These titers will be measured in blood samples collected weekly during the month after vaccination by suitable ELISAs.
Change T=0 and T= 4 weeks
Secondary Outcomes (16)
Immune parameters (1)
T=-1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination
Immune parameters (2)
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Leukocyte count
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Leukocyte differential count
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Fasted metabolism (1)
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
- +11 more secondary outcomes
Study Arms (2)
Plant stanol group
EXPERIMENTALThis arm receives 4g of plant stanols per day (delivered as plant stanol esters) by consuming mini drinks (100 mL each).
Placebo group
PLACEBO COMPARATORThis arm receives mini drinks without added plant stanols (delivered as plant stanol esters).
Interventions
Oat milk based mini drinks (100 mL) containing 2g plant stanols each (delivered as plant stanol esters).
Oat milk based mini drinks (100 mL) without added plant stanols (delivered as plant stanol esters).
First dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
Eligibility Criteria
You may qualify if:
- Men and women
- Aged 18 years or older
- BMI between 27 and 35 kg/m2
- Currently not using products containing plant sterols or stanols (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands)
- Willing to abstain from products containing plant sterols or stanols during the study (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands)
- Willing to keep the intake of fish oil and vitamin supplements constant
You may not qualify if:
- Already received COVID-19 vaccination
- Already had a positive test for COVID-19 (this includes all types of tests, e.g. PCR tests or antibody tests)
- Allergy to an ingredient of the mini drinks
- Having donated blood within one month prior to the start of the study, or planning to donate blood during the study
- Pregnant women
- Breastfeeding women
- Excessive alcohol use (\>20 consumptions per week)
- Regular use of soft or hard drugs
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Maastricht University Medical Centerlead
- Raisio Nutrition Ltd.collaborator
Study Sites (1)
Maastricht University Medical Center
Maastricht, Limburg, 6229ER, Netherlands
Related Publications (1)
van Brakel L, Mensink RP, Lutjohann D, Plat J. Plant stanol consumption increases anti-COVID-19 antibody responses, independent of changes in serum cholesterol concentrations: a randomized controlled trial. Am J Clin Nutr. 2024 Apr;119(4):969-980. doi: 10.1016/j.ajcnut.2024.01.017. Epub 2024 Jan 24.
PMID: 38278364DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jogchum Plat, PhD
Maastricht University Medical Center
- PRINCIPAL INVESTIGATOR
Ronald P Mensink, PhD
Maastricht University Medical Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 13, 2021
First Posted
April 14, 2021
Study Start
April 22, 2021
Primary Completion
January 11, 2022
Study Completion
January 11, 2022
Last Updated
March 2, 2022
Record last verified: 2022-02